Lew Indu
1 Cragwood Rd, Suite 3D, South Plainfield, NJ 07080. E-mail:
Am J Manag Care. 2013 Dec;19(18 Suppl):s376-81.
The management of prostate cancer (PrCa) and especially castration-resistant disease can be complex, challenging, and costly. Significant developments in the field of oncology have led to the further development of safe and effective therapies that are better targeted to particular tumor types and to individual patients. This is evident in castration-resistant prostate cancer (CRPC), where 5 new therapies proved to increase overall survival have debuted in just the past few years. With new therapies, however, come new treatment paradigms and new potential costs. It is vital that managed care clinicians and providers analyze the burden and the costs of cancer in the United States, especially those relating to PrCa and especially CRPC. This will allow a better understanding of how costs and issues relating to healthcare utilization affect the treatment of patients with CRPC, and impact individualized therapy and management decisions.
前列腺癌（PrCa）的管理，尤其是去势抵抗性疾病的管理，可能复杂、具有挑战性且成本高昂。肿瘤学领域的重大进展促使了更安全、有效的疗法进一步发展，这些疗法能更好地针对特定肿瘤类型和个体患者。这在去势抵抗性前列腺癌（CRPC）中表现明显，仅在过去几年就有5种被证明可提高总生存率的新疗法问世。然而，新疗法也带来了新的治疗模式和新的潜在成本。至关重要的是，管理式医疗的临床医生和提供者要分析美国癌症的负担和成本，尤其是与PrCa相关的，特别是CRPC的负担和成本。这将有助于更好地理解与医疗保健利用相关的成本和问题如何影响CRPC患者的治疗，并影响个体化治疗和管理决策。
